What evidence gaps are holding back T-cell receptor therapies?

Why do TCR therapies work so much worse in solid tumors than in blood cancers?

The core problem is that TCR therapies have not yet shown they can reliably shrink solid tumors. A large meta-analysis of 1,250 patients found that objective response rates (complete plus partial responses) for adoptive cell therapies in solid tumors were only 20.1%, compared to 75.4% in blood cancers [1]. That is a massive gap — roughly three out of four blood cancer patients respond, but only one in five solid tumor patients do. The same study found that while TCR therapies outperformed CAR-T cells in solid tumors (odds ratio of 3.1, meaning about three times higher odds of response), the overall response rate was still low [1]. This tells us that even the better-performing TCR approach is far from effective enough for most solid tumor patients.

A key reason for this poor efficacy is that solid tumors are biologically complex. They have an immunosuppressive microenvironment that actively shuts down T cells, and they are highly heterogeneous, meaning different cells within the same tumor may express different targets [2]. TCRs can only recognize their target if the tumor cell presents it on an HLA molecule, and many solid tumor cells downregulate or lose these HLA molecules entirely — a resistance mechanism called HLA loss of heterozygosity [2]. This means that even a perfectly engineered TCR may simply have nothing to bind to on many tumor cells.

What is the evidence gap around finding safe targets?

The second major gap is the shortage of tumor-specific targets that are not also found on healthy tissues. TCRs can recognize intracellular proteins presented on HLA, which opens up a much larger pool of potential targets than CAR-T cells (which only see surface proteins) [5]. However, this also increases the risk of off-tumor toxicity — attacking healthy cells that happen to present the same protein fragment. The meta-analysis found that while severe side effects like cytokine release syndrome (CRS) and neurotoxicity (ICANS) were less common in solid tumor patients than in blood cancer patients (e.g., any-grade CRS 33% vs. 62.4%), the therapies still caused significant toxicities like fever (37.4%), hypotension (18.5%), and hypoxia (8.5%) [1]. These toxicities were not different between TCR and CAR-T therapies, suggesting the delivery platform itself carries risks [1].

Recent reviews emphasize that the field lacks a robust pipeline of validated, truly tumor-exclusive targets [2][5]. Most current targets, like NY-ESO-1 (which showed better responses in the meta-analysis, odds ratio 2.0), are cancer-testis antigens that are also expressed in normal testis tissue, creating a narrow therapeutic window [1][5]. Without better target discovery, the risk of hitting healthy organs remains a major barrier to moving TCR therapies into larger, later-stage trials.

What technical and resistance-related gaps still need to be solved?

A third set of gaps involves the engineering of the T cells themselves and how tumors evolve to escape them. One critical issue is that when you insert a new TCR into a patient's T cells, the introduced TCR can pair with the cell's own endogenous TCR chains, creating mixed receptors that may recognize self-tissues and cause autoimmunity, or simply dilute the potency of the therapeutic TCR [4]. A recent preclinical study showed that using CRISPR to remove both endogenous TCR chains boosted the expression and function of the therapeutic TCR, leading to better tumor clearance in mice and preventing graft-versus-host disease [4]. However, this approach has not yet been tested in human clinical trials, so its real-world safety and benefit remain unknown.

Resistance mechanisms are another poorly understood area. Tumors can lose HLA molecules, mutate the target antigen, or create physical barriers that prevent T cell infiltration [2][5]. The meta-analysis noted that further studies with larger populations and longer follow-up are needed to address the role of these treatments in cancer [1]. The field also lacks standardized methods to predict and monitor these resistance pathways in patients, which is essential for designing combination strategies that could overcome them [3][5].

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2022 to 2026, 3 from 2024 or later, 4 in Q1 journals, collectively cited 363 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 73 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions